RNA CoMPASS: A Dual Approach for Pathogen and Host Transcriptome Analysis of RNA-Seq Datasets

<div><p>High-throughput RNA sequencing (RNA-seq) has become an instrumental assay for the analysis of multiple aspects of an organism's transcriptome. Further, the analysis of a biological specimen's associated microbiome can also be performed using RNA-seq data and this application is gaining interest in the scientific community. There are many existing bioinformatics tools designed for analysis and visualization of transcriptome data. Despite the availability of an array of next generation sequencing (NGS) analysis tools, the analysis of RNA-seq data sets poses a challenge for many biomedical researchers who are not familiar with command-line tools. Here we present RNA CoMPASS, a comprehensive RNA-seq analysis pipeline for the simultaneous analysis of transcriptomes and metatranscriptomes from diverse biological specimens. RNA CoMPASS leverages existing tools and parallel computing technology to facilitate the analysis of even very large datasets. RNA CoMPASS has a web-based graphical user interface with intrinsic queuing to control a distributed computational pipeline. RNA CoMPASS was evaluated by analyzing RNA-seq data sets from 45 B-cell samples. Twenty-two of these samples were derived from lymphoblastoid cell lines (LCLs) generated by the infection of naïve B-cells with the Epstein Barr virus (EBV), while another 23 samples were derived from Burkitt's lymphomas (BL), some of which arose in part through infection with EBV. Appropriately, RNA CoMPASS identified EBV in all LCLs and in a fraction of the BLs. Cluster analysis of the human transcriptome component of the RNA CoMPASS output clearly separated the BLs (which have a germinal center-like phenotype) from the LCLs (which have a blast-like phenotype) with evidence of activated MYC signaling and lower interferon and NF-kB signaling in the BLs. Together, this analysis illustrates the utility of RNA CoMPASS in the simultaneous analysis of transcriptome and metatranscriptome data. RNA CoMPASS is freely available at <a href="http://rnacompass.sourceforge.net/" target="_blank">http://rnacompass.sourceforge.net/</a>.</p></div

Performance Analysis of RNA CoMPASS.

<p>RNA CoMPASS was deployed on a local cluster and benchmarking was performed. An Akata RNA-seq data set was split into six files of varying sizes: 1–393.4 MB, 1,397,139 reads, 2–757 MB, 2,685,149 reads, 3–1.44 GB, 5,120,805 reads, 4–2.72 GB, 9,651,466 reads, 5–5.01 GB, 25,465,406 reads, sample 6–8.99 GB, 50,930,812 reads. Overall time was calculated for each file on a single machine (blue column) and on the local 4-node cluster (red column). Speedup time is represented as a green line.</p

Heat Map representing Human B-Cells analyzed using RNA CoMPASS.

<p>Human transcript counts from the 45 B-cell samples were imported into the R software environment and analyzed using the edgeR package <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0089445#pone.0089445-Robinson1" target="_blank">[15]</a>. Genes with low transcript counts (less than 1 CPM (count per million)) in the majority of samples were filtered out. The Manhattan (L-1) distance matrix for the samples was computed using the remaining transcript counts, and this was taken as input for hierarchical clustering using the Ward algorithm. After assigning each sample to one of two groups identified by hierarchical clustering (Human B-Cell or Burkitt's Lymphoma), the glmFit function was used to fit the mean log(CPM) for each group and likelihood ratio tests were used to identify those genes that were differentially expressed, with adjusted <i>P</i><0.05 following the Benjamini-Hochberg correction for multiple testing. The fitted log(CPM) values for the subset of genes that were differentially expressed in the LCL samples relative to the Burkitt's lymphoma samples were then clustered using the Euclidean distance and complete linkage algorithm to detect groups of co-expressed genes. The expression heat map displays the top 250 differentially expressed genes.</p

Schematic of RNA CoMPASS (RNA comprehensive multi-processor analysis system for sequencing) architecture.

<p>RNA CoMPASS is a graphical user interface (GUI) based parallel computation pipeline for the analysis of both exogenous and human sequences from RNA-seq data. It employs a commercial and several open-source programs to analyze RNA-seq data sets including Novoalign, SAMMate, BLAST, and MEGAN. Each step results in the subtraction of reads in order to further analyze the unmapped reads for pathogen discovery. The mapped reads are analyzed separately. The end result from this pipeline is pathogen discovery and host transcriptome analysis.</p

Differences in Gastric Carcinoma Microenvironment Stratify According to EBV Infection Intensity: Implications for Possible Immune Adjuvant Therapy

<div><p>Epstein-Barr virus (EBV) is associated with roughly 10% of gastric carcinomas worldwide (EBVaGC). Although previous investigations provide a strong link between EBV and gastric carcinomas, these studies were performed using selected EBV gene probes. Using a cohort of gastric carcinoma RNA-seq data sets from The Cancer Genome Atlas (TCGA), we performed a quantitative and global assessment of EBV gene expression in gastric carcinomas and assessed EBV associated cellular pathway alterations. EBV transcripts were detected in 17% of samples but these samples varied significantly in EBV coverage depth. In four samples with the highest EBV coverage (hiEBVaGC – high EBV associated gastric carcinoma), transcripts from the BamHI A region comprised the majority of EBV reads. Expression of LMP2, and to a lesser extent, LMP1 were also observed as was evidence of abortive lytic replication. Analysis of cellular gene expression indicated significant immune cell infiltration and a predominant IFNG response in samples expressing high levels of EBV transcripts relative to samples expressing low or no EBV transcripts. Despite the apparent immune cell infiltration, high levels of the cytotoxic T-cell (CTL) and natural killer (NK) cell inhibitor, IDO1, was observed in the hiEBVaGCs samples suggesting an active tolerance inducing pathway in this subgroup. These results were confirmed in a separate cohort of 21 Vietnamese gastric carcinoma samples using qRT-PCR and on tissue samples using in situ hybridization and immunohistochemistry. Lastly, a panel of tumor suppressors and candidate oncogenes were expressed at lower levels in hiEBVaGC versus EBV-low and EBV-negative gastric cancers suggesting the direct regulation of tumor pathways by EBV.</p> </div